TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment of APL
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Modern treatment programs for acute promyelocytic leukemia (APL) are based on the sensitivity of leukemia cells to the differentiation-inducing and apoptotic effects of tretinoin and arsenic trioxide. APL therapy first diverged from the therapy of other non-APL subtypes of acute myeloid leukemia (AML) with the addition of tretinoin to chemotherapy. With the incorporation of arsenic trioxide into modern treatment regimens, the use of traditional chemotherapy in adults and children is restricted to only the induction phase for high-risk patients.[1-3]
Treatment options for children with APL may include the following:
Arsenic trioxide and tretinoin, with or without chemotherapy.
Source links and citations
Supportive care.
Continue within this section
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice